GSK 2879552

Drug Profile

GSK 2879552

Alternative Names: GSK-2879552

Latest Information Update: 11 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline
  • Class Antineoplastics
  • Mechanism of Action Co-repressor protein inhibitors; Lysine specific demethylase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Myelodysplastic syndromes
  • Phase I Acute myeloid leukaemia; Small cell lung cancer

Most Recent Events

  • 14 Dec 2017 GlaxoSmithKline terminates phase I trial in Acute myeloid leukaemia (Second-line therapy or greater) in USA, Canada, Australia (PO) (NCT02177812)
  • 01 Aug 2017 GlaxoSmithKline terminates a phase I trial for Small cell lung cancer (Second-line therapy or greater) in USA, France and Spain (NCT02034123)
  • 31 Jul 2017 Phase-I/II clinical trials in Myelodysplastic syndromes in USA (PO) (NCT02929498)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top